Last reviewed · How we verify
IPV at 6 and fIPV at 22 weeks, RotaTeq
IPV at 6 and fIPV at 22 weeks, RotaTeq is a Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved.
IPV at 6 and fIPV at 22 weeks, along with RotaTeq, are marketed vaccines managed by the Centers for Disease Control and Prevention. A key strength is the protection against polio and rotavirus, leveraging a well-established mechanism with a key composition patent expiring in 2028. The primary risk is the potential for increased competition as the patent nears expiration.
At a glance
| Generic name | IPV at 6 and fIPV at 22 weeks, RotaTeq |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPV at 6 and fIPV at 22 weeks, RotaTeq CI brief — competitive landscape report
- IPV at 6 and fIPV at 22 weeks, RotaTeq updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI